Abstract Number: 2622 • 2013 ACR/ARHP Annual Meeting
Comparison Of Different Methods Of Skin Pathergy Test In Patients With Behçet’s Syndrome
Background/Purpose: Skin pathergy test (SPT) has a diagnostic value in Behçet’s syndrome (BS). There are different descriptions of the test which may effect its positivity rate.…Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…Abstract Number: 2624 • 2013 ACR/ARHP Annual Meeting
Evaluation of Asymptomatic Venous Disease By Venous Doppler Ultrasonography in Patients With Behcet’s Disease
Background/Purpose: One of the major causes of mortality and morbidity in Behcet’s disease (BD), especially in young males of Mediterranean origin, is vascular involvement. A…Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…Abstract Number: 2626 • 2013 ACR/ARHP Annual Meeting
Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet’s Syndrome
Background/Purpose: Uncontrolled studies suggest a beneficial effect of infliximab in the treatment of severe uveitis of BS. The majority of these studies had short observation…Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting
Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…Abstract Number: 2630 • 2013 ACR/ARHP Annual Meeting
Low Medication Adherence Is Observed In Behcet’s Disease
Background/Purpose: Symptom-control with reduction of mortality and morbidityare the main treatment goalsin Behcet’s Disease (BD). However, similar to other chronic disorders, increased unnecessary visits, hospitalisation…Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting
Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…Abstract Number: 2633 • 2013 ACR/ARHP Annual Meeting
Clinical Spectrum Of Cutaneous Vasculitis
Background/Purpose: Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is…Abstract Number: 2634 • 2013 ACR/ARHP Annual Meeting
Henoch-Schönlein Purpura: Clinical Spectrum Of The Disease In 417 Patients From A Single Center
Background/Purpose: The severity of clinical features and the outcome in the different series of Henoch-Schönlein Purpura (HSP) shows great variability, probably due to selection-bias. Our…Abstract Number: 2595 • 2013 ACR/ARHP Annual Meeting
Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease
Background/Purpose: To analyze the morphological and functional abnormalities of the microcirculation through widefield nailfold capillaroscopy (NFC), videocapillaroscopy and cutaneous microvascular blood flow measurement before and…Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
ACR Meeting Abstracts